Strategy Includes Acquisition and Commercialization of Adoptive Cell Immunotherapy Technology
LOS ANGELES, March 16, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced it is expanding its therapeutic strategy to include active immunotherapies to treat various cancers. The Company will focus on establishing a therapeutic development program based on Adoptive Cell Immunotherapy. The new strategy will be discussed during a presentation today at the Roth Capital Growth Stock Conference in Laguna Niguel, California.
"Adoptive Cell Immunotherapy, which utilizes cells from a patient's own immune system to treat cancer, is one of the most promising areas of oncology," said Anthony J. Cataldo, President and Chief Executive Officer. "The strategy to develop active immunotherapies complements our current passive immunotherapy platform based on GBP-102, our Anti-CD55+ therapeutic antibody candidate," stated Mr. Cataldo.
"Presently we are working to bring together the necessary intellectual property and technology assets, along with the scientific and manufacturing expertise to build out a commercial-scale Adoptive Cell Immunotherapy program," said Mr. Cataldo.
About Genesis Biopharma, Inc.
Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies. For more information about the company, visit www.genesis-biopharma.com.
The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential," "suggests," "bodes," "may," "should," "could" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
SOURCE Genesis Biopharma, Inc.